Glimpiride

# Glimpiride ## Overview - **Classification**: Sulfonylurea, Antidiabetic agent - **Mechanism**: Stimulates insulin release from pancreatic beta cells by binding to sulfonylurea receptors, closing ATP-sensitive potassium channels. Also enhances peripheral insulin sensitivity. ## Primary Indications 1. **Type 2 Diabetes Mellitus (T2DM)** - As an adjunct to diet and exercise to improve glycemic control. 2. **T2DM (Combination Therapy)** - Used in combination with metformin or insulin when monotherapy is insufficient. ## Adult Dosing ### Standard Dosing **Type 2 Diabetes Mellitus** - **Dose**: Initial: **1-2 mg** daily - **Frequency**: Once daily, with breakfast or first main meal - **Route**: Oral - **Maximum Dose**: **8 mg** daily ### Dose Adjustments - **Renal Impairment**: Initial **1 mg** daily. Max **2 mg** daily for CrCl < 22 mL/min. Use with caution. - **Hepatic Impairment**: Initiate low and titrate slowly. Use with extreme caution and monitor liver function tests. - **Elderly Patients**: Start with **1 mg** daily. Titrate slowly due to increased hypoglycemia risk and potential organ impairment. ## Pediatric Dosing *Glimpiride is generally **not recommended** for pediatric patients (0-18 years) due to insufficient data on safety and efficacy, and a higher risk of hypoglycemia.* ### Neonates (0-28 days) - **Dose**: Not recommended. - **Frequency**: Not applicable. - **Maximum**: Not applicable. - **Special Notes**: Safety and efficacy not established. High risk of severe and prolonged hypoglycemia. ### Infants (1-12 months) - **Dose**: Not recommended. - **Frequency**: Not applicable. - **Maximum**: Not applicable. - **Special Notes**: Safety and efficacy not established. Infants are particularly vulnerable to hypoglycemia. ### Children (1-12 years) - **Dose**: Not recommended. - **Frequency**: Not applicable. - **Maximum**: Not applicable. - **Special Notes**: Safety and efficacy not established. Consider alternative agents for glycemic control. ### Adolescents (13-18 years) - **Dose**: Not recommended. - **Frequency**: Not applicable. - **Maximum**: Not applicable. - **Special Notes**: Safety and efficacy not established. Increased risk of hypoglycemia compared to adults. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to glimepiride, other sulfonylureas, or sulfonamides. - **Absolute**: Diabetic Ketoacidosis (DKA), Type 1 Diabetes Mellitus. - **Absolute**: Pregnancy (Category C), Breastfeeding. ### Common Adverse Effects - **Very Common (>10%)**: Hypoglycemia (dose-dependent, most common). - **Common (1-10%)**: Dizziness, asthenia, headache, nausea, mild gastrointestinal disturbances. - **Serious but Rare**: Agranulocytosis, aplastic anemia, hemolytic anemia, cholestatic jaundice, severe skin reactions (e.g., SJS). ### Key Drug Interactions - **Beta-blockers, Alcohol, NSAIDs, Salicylates, Fluconazole, Sulfonamides**: Increase hypoglycemia risk by potentiating glimepiride's effect. - **Thiazide diuretics, Corticosteroids, Sympathomimetics, Thyroid hormones**: Decrease glimepiride's hypoglycemic effect (increase blood glucose). - **Warfarin**: May potentiate or weaken anticoagulant effect; monitor INR closely when co-administered. ## Monitoring & Follow-up - **Before Treatment**: Baseline A1C, Fasting Blood Glucose (FBG), renal (SCr, eGFR) and hepatic (LFTs) function. - **During Treatment**: FBG and Self-Monitoring Blood Glucose (SMBG) regularly. A1C every 3-6 months. Periodically re-assess renal and hepatic function. - **Clinical Signs**: Monitor patients for symptoms of hypoglycemia (e.g., sweating, tremor, hunger, confusion, blurred vision). ## Clinical Pearls - 💡 **Tip 1**: Always take glimepiride with breakfast or the first main meal to minimize the risk of hypoglycemia. - 💡 **Tip 2**: Educate patients thoroughly on recognizing and treating hypoglycemia. Advise carrying a rapid-acting carbohydrate. - 💡 **Tip 3**: Glimepiride can cause weight gain; counsel patients on dietary management and regular exercise. - 💡 **Tip 4**: Patients with a known sulfa allergy may have cross-sensitivity to glimepiride; use with caution. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.